Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 12/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30084901 | 1.00 | GLA (0.55) | GLAPOLBGAATSHRKDM4E | |
| SCHEMBL29396844 | 0.84 | AR (0.56) | GLAPOLBGAATSHRAR | |
| SCHEMBL110567 | 0.84 | AR (0.56) | GLAPOLBGAATSHRAR | |
| SCHEMBL23910089 | 0.80 | KDM4E (0.45) | GLAPOLBGAATSHRKDM4E | |
| SCHEMBL397540 | 0.80 | KDM4E (0.52) | GLAPOLBGAATSHRKDM4E | |
| SCHEMBL30279017 | 0.80 | KDM4E (0.52) | GLAPOLBGAATSHRKDM4E | |
| SCHEMBL5203682 | 0.78 | KIF11 (0.53) | ARSLC22A12KIF11 | |
| SCHEMBL1996176 | 0.78 | AR (0.53) | ARSLC22A12KIF11 | |
| SCHEMBL325632 | 0.78 | AR (0.50) | GAAKDM4EALDH1A1ARSLC22A12 | |
| SCHEMBL29421468 | 0.78 | AR (0.50) | GAAKDM4EALDH1A1ARSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003114-A | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2019-07-12 | — | — | CN | claimed |
| US-20260049068-A1 | Substituted Tetrazolyl Compounds Useful as T Cell Activators | BRISTOL MYERS SQUIBB CO (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4568950-A1 | SUBSTITUTED TETRAZOLYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025108301-A1 | FURAN RING-CONTAINING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 武汉熙瑞医药科技有限公司 | 2025-05-30 | — | — | WO | disclosed |
| WO-2024149389-A1 | SUBSTITUTED BRIDGE RING INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 苏州泽璟生物制药股份有限公司 | 2024-07-18 | — | — | WO | disclosed |
| WO-2024036100-A1 | SUBSTITUTED TETRAZOLYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023244059-A1 | METHODS OF TREATING CANCER USING DUAL ANDROGEN RECEPTOR AND PDE5 INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-12-21 | — | — | WO | disclosed |
| EP-4259634-A1 | NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR | Ildong Pharmaceutical Co., Ltd. (KR) | 2023-10-18 | — | — | EP | disclosed |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-05-31 | — | — | US | disclosed |
| EP-1620413-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004098494-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-1144366-A3 | USE OF ANDROGEN RECEPTOR SUPPRESSORS | BIOPHYSICA, INC. (US) | 2003-06-04 | — | — | EP | disclosed |
| WO-2001058855-A9 | USE OF ANDROGEN RECEPTOR SUPPRESSORS | BIOPHYSICA INC (US) | 2002-10-31 | — | — | WO | disclosed |
| US-6472415-B1 | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes | BIOPHYSICA, INC. | 2002-10-29 | — | — | US | disclosed |
| EP-1144366-A2 | USE OF ANDROGEN RECEPTOR SUPPRESSORS | BIOPHYSICA, INC. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001058855-A1 | USE OF ANDROGEN RECEPTOR SUPPRESSORS | BIOPHYSICA, INC (US) | 2001-08-16 | — | — | WO | disclosed |
| US-6184249-B1 | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes | BIOPHYSICA, INC. | 2001-02-06 | — | — | US | disclosed |
| WO-2000037430-A2 | USE OF ANDROGEN RECEPTOR SUPPRESSORS | BIOPHYSICA, INC. (US) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | PDE5A, AR, PDE3A | GLA 2095/4885POLB 1234/4885GAA 3177/4885 |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | AR, SHBG, ESRRA | GLA 686/4885POLB 2764/4885GAA 1122/4885 |
| US-20260049068-A1 | Substituted Tetrazolyl Compounds Useful as T Cell Activators | DGKZ, DGKA, DGKG | GLA 1384/4885POLB 2031/4885GAA 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.